Adiseshaiah Pavan P, Patel Nimit L, Ileva Lilia V, Kalen Joseph D, Haines Diana C, McNeil Scott E
Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Small Animal Imaging Program, Laboratory Animal Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Int J Mol Imaging. 2014;2014:102702. doi: 10.1155/2014/102702. Epub 2014 Mar 3.
Metastatic spread is the leading cause of death from cancer. Early detection of cancer at primary and metastatic sites by noninvasive imaging modalities would be beneficial for both therapeutic intervention and disease management. Noninvasive imaging modalities such as bioluminescence (optical), positron emission tomography (PET)/X-ray computed tomography (CT), and magnetic resonance imaging (MRI) can provide complementary information and accurately measure tumor growth as confirmed by histopathology. Methods. We validated two metastatic tumor models, MDA-MD-231-Luc and B16-F10-Luc intravenously injected, and 4T1-Luc cells orthotopically implanted into the mammary fat pad. Longitudinal whole body bioluminescence imaging (BLI) evaluated metastasis, and tumor burden of the melanoma cell line (B16-F10-Luc) was correlated with (PET)/CT and MRI. In addition, ex vivo imaging evaluated metastasis in relevant organs and histopathological analysis was used to confirm imaging. Results. BLI revealed successful colonization of cancer cells in both metastatic tumor models over a 4-week period. Furthermore, lung metastasis of B16-F10-Luc cells imaged by PET/CT at week four showed a strong correlation (R (2) = 0.9) with histopathology. The presence and degree of metastasis as determined by imaging correlated (R (2) = 0.7) well with histopathology findings. Conclusions. We validated two metastatic tumor models by longitudinal noninvasive imaging with good histopathology correlation.
转移扩散是癌症致死的主要原因。通过非侵入性成像方式早期检测原发性和转移部位的癌症，对于治疗干预和疾病管理都将有益。诸如生物发光（光学）、正电子发射断层扫描（PET）/X射线计算机断层扫描（CT）以及磁共振成像（MRI）等非侵入性成像方式可以提供互补信息，并能如组织病理学所证实的那样准确测量肿瘤生长。方法。我们验证了两种转移瘤模型，即静脉注射的MDA-MD-231-Luc和B16-F10-Luc，以及原位植入乳腺脂肪垫的4T1-Luc细胞。纵向全身生物发光成像（BLI）评估转移情况，黑色素瘤细胞系（B16-F10-Luc）的肿瘤负荷与PET/CT和MRI相关。此外，离体成像评估相关器官中的转移情况，并使用组织病理学分析来证实成像结果。结果。BLI显示在4周时间内两种转移瘤模型中的癌细胞均成功定植。此外，在第4周通过PET/CT成像的B16-F10-Luc细胞的肺转移与组织病理学显示出很强的相关性（R (2) = 0.9）。通过成像确定的转移的存在和程度与组织病理学结果相关性良好（R (2) = 0.7）。结论。我们通过纵向非侵入性成像验证了两种转移瘤模型，其与组织病理学具有良好的相关性。
